ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Phreesia Named 2022 Best in KLAS for Patient Intake Management for a Fourth Year

Phreesia (NYSE: PHR) is pleased to announce it has been named 2022 Best in KLAS for Patient Intake Management by the research and insights firm KLAS. In its annual report, “2022 Best in KLAS: Software and Services,” KLAS recognized the healthcare IT and services companies who excel in helping healthcare professionals improve patient care.

This is the fourth consecutive year that Phreesia has been recognized as the top-rated patient intake management vendor by KLAS, based on direct feedback from provider organizations.

“Each year, thousands of healthcare professionals across the globe take the time to share their voice with KLAS,” said KLAS CEO Adam Gale. “The Best in KLAS report and the awards it contains set the standard of excellence for software and services firms. Vendors who win the title of Best in KLAS should celebrate and remember that providers now accept only the best from their products and services. The Best in KLAS award serves as a signal to provider and payer organizations that they should expect excellence from the winning vendors.”

The Best in KLAS designation is reserved for the software and services market segments that have the broadest operational and clinical impact on healthcare organizations.

Phreesia earned an overall top score of 90.0, based on provider feedback across a range of customer experience pillars, including culture, loyalty, operations, product, relationship and value.

Phreesia’s platform helps provider healthcare organizations automate the patient outreach and intake process, including operational services such as self-service registration, self-scheduling, insurance verification and patient payments, clinical screenings such as patient-reported outcomes (PROs) and social determinants of health (SDOH), and tools to engage patients and improve outcomes. Phreesia also has the exclusive worldwide license for the Patient Activation Measure® (PAM), which is widely viewed as the gold standard for measuring a patient’s knowledge, skills and confidence to manage their own care.

“We’re thrilled to once again be ranked as the top-performing patient intake platform,” said Phreesia’s CEO Chaim Indig. “This achievement is made possible by the trust and support of our clients and the hard work of our team members. We remain committed to investing in our platform and our organization to give healthcare providers the tools they need to support their patients and staff.”

About Phreesia

Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, convenient experience, while enabling our clients to enhance clinical care and drive efficiency.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.53
+0.42 (0.18%)
AAPL  278.78
-1.92 (-0.68%)
AMD  217.97
+1.99 (0.92%)
BAC  53.95
+0.07 (0.13%)
GOOG  322.09
+3.70 (1.16%)
META  673.42
+11.89 (1.80%)
MSFT  483.16
+2.32 (0.48%)
NVDA  182.41
-0.97 (-0.53%)
ORCL  217.58
+3.25 (1.52%)
TSLA  455.00
+0.47 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.